Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders, announced today that Gustav Christensen, President and Chief Executive Officer, and Burt Adelman, M.D., Executive Vice President and Chief Medical Officer, will participate in the Leerink Swann Rare Disease Roundtable on Wednesday, October 2, 2013 at Le Parker Meridien in New York City and are scheduled to present at 9:00 AM ET that day.
Help employers find you! Check out all the jobs and post your resume.
